Leukemia & lymphoma · 2026
Comparative outcomes of lisocabtagene maraleucel versus an external control arm in third-line or later relapsed or refractory follicular lymphoma.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nastoupil Loretta Jo, Martín García-Sancho Alejandro, Izutsu Koji, Cartron Guillaume, Zausner Skarbnik Alan Pierre, Reguera Ortega Juan Luis, Goto Hideki, Borchmann Peter, Farazi Thalia, Bar Merav, Del Rosario Olivera Maria, Kumar Jinender, De Benedetti Marc, Gu Fangyi, Stein Dara, Han Jenny, Palomba Maria Lia
Аннотация
In TRANSCEND FL, lisocabtagene maraleucel (liso-cel) demonstrated strong efficacy, with 97% overall response rate (ORR) and 94% complete response (CR) rate in third-line or later (3 L+) follicular lymphoma (FL). Here, we compared efficacy and safety of liso-cel from TRANSCEND FL to standard-of-care (SOC [excluding T-cell-engaging therapies]) by constructing an external control arm (ECA) of patients from historical clinical trials and real-world practice. Using inverse probability of treatment weighting (IPTW), ECA cohort was balanced to match TRANSCEND FL. After IPTW, liso-cel-treated patients had significantly higher ORR (relative risk: 1.4; 95% confidence interval [CI]: 1.3-1.6) and CR rate (2.4; 2.1-2.7) than SOC. Adjusted hazard ratios (95% CI) for duration of response (0.26; 0.15-0.46), time to next treatment (0.24; 0.13-0.44), progression-free survival (0.28; 0.17-0.48), and overall survival (0.40; 0.19-0.84) significantly favored liso-cel, demonstrating meaningful efficacy improvement with liso-cel over SOC, solidifying liso-cel as a treatment option for patients with 3 L + FL.